Medtronic to Develop Stent Graft System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms Under Exclusive Patent ...
April 14 2015 - 11:00AM
Collaboration Aims
to Expand Treatment Options and Improve Outcomes for
Patients
DUBLIN, Ireland and SIOUX FALLS,
S.D. -- April 14, 2015 -- The global leader in medical
technology for endovascular aortic repair (EVAR), Medtronic plc
(NYSE: MDT) today announced that it plans to develop a stent graft
system for less invasive treatment of thoracoabdominal aortic
aneurysms under an exclusive patent license agreement with South
Dakota-based Sanford Health.
A concept for the novel system, which was
described in the November 2014 issue of the Journal of Vascular
Surgery, is currently being studied
(NCT02294435) under a physician-sponsored (PS) investigational
device exemption (IDE) recently approved by the U.S. Food and Drug
Administration (FDA). Sanford Health vascular surgeon Patrick
Kelly, MD, the physician sponsor of the PS IDE, developed the
concept for the system and has since collaborated with
Medtronic to manufacture devices based on the concept.
Sanford Health holds the intellectual property
covered by the exclusive patent license agreement with Medtronic.
Medtronic plans to study the system in collaboration with
physicians at several medical centers, including Dr. Kelly at
Sanford Health, starting in the near future and subsequently to
commercialize it after obtaining the required regulatory
approvals.
Dr. David Pearce, president of Sanford Research,
believes this type of translational research is important to his
organization's mission. "Our culture at Sanford Health and at
Sanford Research is one that supports the problem-solving
innovation that's needed to bring medical advancements to market
and to patients. Dr. Kelly's ingenuity is providing a treatment
option to patients who may not be eligible for any other approach
for repairing their aneurysm," Dr. Pearce said.
Dr. Kelly added: "Taking the complex and making it
simple has long been our goal for the treatment of thoracoabdominal
aneurysms. Working with Medtronic could eventually place our
solution in the hands of vascular surgeons around the world to help
patients facing a life-threatening condition. We hope that this
will have a major impact on the treatment of one of the most
challenging disease processes to face our specialty."
"We're very excited to be working with Dr. Kelly
and Sanford Health to develop a standardized stent graft system to
address the clinical challenges of repairing thoracoabdominal
aortic aneurysms," said Daveen Chopra, vice president and general
manager of the Aortic franchise at Medtronic. "The exclusive patent
license agreement that we've entered into with Sanford Health is a
further demonstration of how Medtronic collaborates with physicians
to foster innovation and develop new therapies that lead to better
patient care."
Medtronic is the long-standing leader in medical
technology for endovascular aortic repair. Medtronic stent grafts
have been used to treat more than 400,000 patients worldwide since
1999 -- more than those from any other company.
ABOUT AORTIC
ANEURYSMS
The aorta is the body's main artery, originating at the top of the
heart's left ventricle and terminating at the iliac bifurcation in
the abdomen. An aortic aneurysm is a dangerous bulge or ballooning
in a segment of the wall of the aorta that can rupture and cause
sudden death if left untreated. The condition affects an estimated
1.3 million people in the United States alone.
Aortic aneurysms can be classified by anatomical
location, including thoracic, abdominal and thoracoabdominal.
Thoracoabdominal aortic aneurysms -- the rarest type, with a U.S.
prevalence of several thousand patients -- start in the thorax and
extend through the abdomen; they generally involve the branch
arteries that supply blood to the liver, spleen, intestine, kidney
and other organs, making them especially challenging to treat. Most
patients with a thoracoabdominal aortic aneurysm have limited
treatment options and are considered at high-risk for open surgical
repair.
MULTIMEDIA RELEASE
A multimedia version of this release, with animation and a graphic
can be found at: http://bit.ly/1GDo8zC
ABOUT SANFORD
HEALTH
Sanford Health (www.sanfordhealth.org) is an integrated health
system headquartered in the Dakotas. It is the largest, rural,
not-for-profit health care system in the nation with 43 hospitals
and 243 clinics in nine states and three countries. With 27,000
employees, including 1,400 physicians in more than 80 specialty
areas of medicine, Sanford Health is the largest employer in the
Dakotas.
ABOUT MEDTRONIC
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is the global leader in medical technology -- alleviating
pain, restoring health and extending life for millions of people
around the world.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
- end -
Contacts:
Joe McGrath
Medtronic
Public Relations
+1-707-591-7367
Stacy Jones
Sanford Health
Public Relations
+1-605-366-2432
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1910842
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2024 to May 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From May 2023 to May 2024